Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 7/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15710993 | 0.94 | CES2 (0.69) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL10026752 | 0.86 | CES2 (0.48) | CES2ALDH1A1FAAHCES1MEN1 | |
| SCHEMBL18751670 | 0.84 | CES2 (0.43) | CES2TSHRALDH1A1KMT2AHSD17B10 | |
| SCHEMBL15946950 | 0.83 | CES2 (0.46) | CES2TSHRALDH1A1FAAHMEN1 | |
| SCHEMBL17913990 | 0.83 | CES2 (0.46) | CES2TSHRALDH1A1FAAHMEN1 | |
| SCHEMBL25725933 | 0.81 | CES2 (0.42) | CES2TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL26353810 | 0.81 | CES2 (0.42) | CES2TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL26261906 | 0.81 | CES2 (0.44) | CES2ALDH1A1 | |
| SCHEMBL12031567 | 0.81 | CES2 (0.48) | CES2TSHRALDH1A1 | |
| SCHEMBL17208236 | 0.80 | ALDH1A1 (0.46) | CES2TSHRALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022040-A1 | ANTIMICROBIALS | AMPLYX PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022040-A1 | ANTIMICROBIALS | PAM, MPO, OXA1L | CES2 149/4885TSHR 4866/4885ALDH1A1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.